Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

61. Pulmonary Embolism Imaging in Canada

Pulmonary Embolism Imaging in Canada Pulmonary Embolism Imaging in Canada | CADTH.ca Find the information you need Pulmonary Embolism Imaging in Canada Pulmonary Embolism Imaging in Canada Published on: November 8, 2016 Project Number: ES0307-000 Product Line: Result type: Report Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. . The “Projects (...) in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. . CADTH is undertaking an environmental scan to identify and summarize information regarding pulmonary embolism (PE) imaging in Canada. The scan will describe current practice, challenges, and enablers in diagnosing PE, and the availability of tests, scans, and tools for diagnosing PE. The key objectives

Canadian Agency for Drugs and Technologies in Health - Environmental Scanning2016

62. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model

Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model 27174887 2016 09 01 2016 09 01 1399-3003 48 3 2016 Sep The European respiratory journal Eur. Respir. J. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. 780-6 10.1183/13993003.00024-2016 The European Society of Cardiology (ESC) has proposed an updated risk stratification model for death in patients with acute (...) pulmonary embolism based on clinical scores (Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI)), right ventricle dysfunction (RVD) and elevated serum troponin (2014 ESC model).We assessed the ability of the 2014 ESC model to predict 30-day death after acute pulmonary embolism. Consecutive patients with symptomatic, confirmed pulmonary embolism included in prospective cohorts were merged in a collaborative database. Patients' risk was classified as high (shock or hypotension

EvidenceUpdates2016

63. The High Risk of Contrast-induced Nephropathy in Patients with Suspected Pulmonary Embolism Despite Three Different Prophylaxis: A Randomized Controlled Trial

The High Risk of Contrast-induced Nephropathy in Patients with Suspected Pulmonary Embolism Despite Three Different Prophylaxis: A Randomized Controlled Trial 27411777 2016 09 27 2016 10 07 1553-2712 23 10 2016 Oct Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med The High Risk of Contrast-induced Nephropathy in Patients with Suspected Pulmonary Embolism Despite Three Different Prophylaxis: A Randomized Controlled Trial. 1136-1145 (...) 10.1111/acem.13051 The objective was to compare the protective effects of N-acetylcysteine (NAC) plus normal saline (NS), sodium bicarbonate (NaHCO3 ) plus NS, and NS alone in the prevention of contrast-induced nephropathy (CIN) after computed tomography pulmonary angiography (CTPA) in emergency patients. This study was planned as a randomized, controlled clinical research. Patients undergoing contrast-enhanced CTPA on suspicion of pulmonary embolism (PE) in the emergency department and with at least

EvidenceUpdates2016

64. Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol

Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol | CADTH.ca CADTH Document Viewer Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Table of Contents Search this document Addendum to Optimal Strategies (...) for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol October 2016 Ethics Review This protocol was written a priori and will be followed throughout the review process. There are two broad normative questions to consider regarding diagnosis of acute pulmonary embolism (PE): Should we provide diagnosis of acute PE? If yes, which strategies should be provided, and how best should those strategies be provided to diagnose those with acute PE? Both of these questions

CADTH - Optimal Use2016

65. Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol

Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol | CADTH.ca CADTH Document Viewer Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Table of Contents Search this document Addendum to Optimal Strategies (...) for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol October 2016 Ethics Review This protocol was written a priori and will be followed throughout the review process. There are two broad normative questions to consider regarding diagnosis of acute pulmonary embolism (PE): Should we provide diagnosis of acute PE? If yes, which strategies should be provided, and how best should those strategies be provided to diagnose those with acute PE? Both of these questions

CADTH - Optimal Use2016

66. Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope.

Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. BACKGROUND: The prevalence of pulmonary embolism among patients hospitalized for syncope is not well documented, and current guidelines pay little attention to a diagnostic workup for pulmonary embolism in these patients. METHODS: We performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals in Italy for a first episode of syncope, regardless of whether there were alternative explanations (...) for the syncope. The diagnosis of pulmonary embolism was ruled out in patients who had a low pretest clinical probability, which was defined according to the Wells score, in combination with a negative d-dimer assay. In all other patients, computed tomographic pulmonary angiography or ventilation-perfusion lung scanning was performed. RESULTS: A total of 560 patients (mean age, 76 years) were included in the study. A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patients (58.9%) on the basis

NEJM2016

67. Percutaneous mechanical thrombectomy for pulmonary embolism

Percutaneous mechanical thrombectomy for pulmonary embolism Percutaneous mechanical thrombectomy for pulmonary embolism Percutaneous mechanical thrombectomy for pulmonary embolism HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Percutaneous mechanical thrombectomy for pulmonary embolism. Lansdale: HAYES, Inc.. Directory Publication. 2016 (...) alone has failed or is contraindicated. However, the technology is invasive and relatively new, warranting assessment of effectiveness, safety, and the performance of the different commercially available devices. Relevant Questions: For patients with pulmonary embolism (PE), is PMT effective for eliminating thromboses and emboli, restoring blood flow and vascular function, and preventing damage to tissues and organs? Are PMT devices safe? How do PMT devices compare with other standard treatments

Health Technology Assessment (HTA) Database.2016

68. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II

Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II 27411591 2016 09 27 2016 09 27 0340-6245 116 4 2016 Sep 27 Thrombosis and haemostasis Thromb. Haemost. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. 714-21 10.1160/TH16-04-0271 Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran (...) had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabigatran versus warfarin according to the index event that qualified the patient for enrollment, either symptomatic pulmonary embolism (PE) with or without deep-vein thrombosis (DVT), or DVT alone. We then analyse the anticoagulant effect of dabigatran vs warfarin on patients enrolled with PE. The pooled dataset

EvidenceUpdates2016

69. Optimal Imaging for Suspected Acute Pulmonary Embolism

Optimal Imaging for Suspected Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism | CADTH.ca Find the information you need Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Published on: August 4, 2016 Project Number: OP0528 Product Line: Research Type: Other Diagnostics Result type: Report Projects listed as “in progress” are at various stages and points of completion (...) . These products have different processes and timelines; therefore, the timing of posting of the final reports varies. . The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. . Pulmonary embolism (PE) is a blockage of one of the arteries in the lung, frequently caused by a blood clot that has travelled to the lung from another part of the body

CADTH - Optimal Use2016

70. Optimal Diagnosis for Suspected Acute Pulmonary Embolism

Optimal Diagnosis for Suspected Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism | CADTH.ca Find the information you need Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Published on: August 4, 2016 Project Number: OP0528 Product Line: Research Type: Other Diagnostics Result type: Report Projects listed as “in progress” are at various stages and points of completion (...) . These products have different processes and timelines; therefore, the timing of posting of the final reports varies. . The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. . Pulmonary embolism (PE) is a blockage of one of the arteries in the lung, frequently caused by a blood clot that has travelled to the lung from another part of the body

CADTH - Optimal Use2016

71. Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism

Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism | CADTH.ca Find the information you need Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Published on: August 4, 2016 Project Number: OP0528 Product Line: Research Type: Other Diagnostics Result type: Report Projects listed as “in progress” are at various stages and points of completion (...) . These products have different processes and timelines; therefore, the timing of posting of the final reports varies. . The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. . Pulmonary embolism (PE) is a blockage of one of the arteries in the lung, frequently caused by a blood clot that has travelled to the lung from another part of the body

CADTH - Optimal Use2016

72. On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism

On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism 27208461 2016 06 24 2017 04 13 2017 04 13 1879-2472 143 2016 Jul Thrombosis research Thromb. Res. On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism. 76-85 10.1016/j.thromres.2016.05.010 S0049-3848(16)30340-1 Acute symptomatic pulmonary embolism (PE) varies in its clinical manifestations in patients with cancer and entails specific issues (...) . The objective is to assess the performance of five scores (PESI, sPESI, GPS, POMPE, and RIETE) and a clinical decision rule to predict 30-day mortality. This is an ambispective, observational, multicenter study that collected episodes of PE in patients with cancer from 13 Spanish centers. The main criterion for comparing scales was the c-indices and 95% confidence intervals (CIs) of the models for predicting 30-day mortality. 585 patients with acute symptomatic PE were recruited. The 30-day mortality rate

EvidenceUpdates2016

73. Deep vein thrombosis and pulmonary embolism.

Deep vein thrombosis and pulmonary embolism. Deep vein thrombosis and pulmonary embolism, collectively referred to as venous thromboembolism, constitute a major global burden of disease. The diagnostic work-up of suspected deep vein thrombosis or pulmonary embolism includes the sequential application of a clinical decision rule and D-dimer testing. Imaging and anticoagulation can be safely withheld in patients who are unlikely to have venous thromboembolism and have a normal D-dimer. All other (...) patients should undergo ultrasonography in case of suspected deep vein thrombosis and CT in case of suspected pulmonary embolism. Direct oral anticoagulants are first-line treatment options for venous thromboembolism because they are associated with a lower risk of bleeding than vitamin K antagonists and are easier to use. Use of thrombolysis should be limited to pulmonary embolism associated with haemodynamic instability. Anticoagulant treatment should be continued for at least 3 months to prevent

Lancet2016

74. Comparison of risk assessment strategies for not-high-risk pulmonary embolism

Comparison of risk assessment strategies for not-high-risk pulmonary embolism 26743479 2016 04 02 2017 02 09 2017 02 09 1399-3003 47 4 2016 Apr The European respiratory journal Eur. Respir. J. Comparison of risk assessment strategies for not-high-risk pulmonary embolism. 1170-8 10.1183/13993003.01605-2015 We compared the prognostic performance of the 2014 European Society of Cardiology (ESC) risk stratification algorithm with the previous 2008 ESC algorithm, the Bova score and the modified FAST (...) score (based on a positive heart-type fatty acid-binding protein (H-FABP) test, syncope and tachycardia, modified using high-sensitivity troponin T instead of H-FABP) in 388 normotensive pulmonary embolism patients included in a single-centre cohort study.Overall, 25 patients (6.4%) had an adverse 30-day outcome. Regardless of the score or algorithm used, the rate of an adverse outcome was highest in the intermediate-high-risk classes, while all patients classified as low-risk had a favourable

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

75. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.

Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. OBJECTIVE: To assess the risk of pulmonary embolism, ischaemic stroke, and myocardial infarction associated with combined oral contraceptives according to dose of oestrogen (ethinylestradiol) and progestogen. DESIGN: Observational cohort study. SETTING: Data from the French national health insurance database linked with data from the French (...) national hospital discharge database. PARTICIPANTS: 4 945 088 women aged 15-49 years, living in France, with at least one reimbursement for oral contraceptives and no previous hospital admission for cancer, pulmonary embolism, ischaemic stroke, or myocardial infarction, between July 2010 and September 2012. MAIN OUTCOME MEASURES: Relative and absolute risks of first pulmonary embolism, ischaemic stroke, and myocardial infarction. RESULTS: The cohort generated 5 443 916 women years of oral

BMJ2016 Full Text: Link to full Text with Trip Pro

76. Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism

Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism 26897283 2016 04 06 2016 12 20 2016 12 30 1879-2472 140 2016 Apr Thrombosis research Thromb. Res. Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism. 46-50 10.1016/j.thromres.2016.02.010 S0049-3848(16)30037-8 Chronic inflammatory diseases predispose for development of a first pulmonary embolism (PE). Previous studies showed that corticosteroids, which are the mainstay of treatment (...) for inflammatory diseases, enhance the risk of a first venous thromboembolism. Yet, it is unknown whether corticosteroids also predispose for recurrent events. Therefore, we investigated the association between oral and/or inhaled corticosteroid use and the risk of recurrent PE. We performed a nested case-control study using the PHARMO Database. Adult patients who had suffered from a first PE for which vitamin K antagonists were prescribed, were eligible. Of these, 384 patients with recurrent PE were matched

EvidenceUpdates2016

77. Investigation and treatment of pulmonary embolism as a potential etiology may be important to improve post‐resuscitation prognosis in non‐shockable out‐of‐hospital cardiopulmonary arrest: report on an analysis of the SOS‐KANTO 2012 study

Investigation and treatment of pulmonary embolism as a potential etiology may be important to improve post‐resuscitation prognosis in non‐shockable out‐of‐hospital cardiopulmonary arrest: report on an analysis of the SOS‐KANTO 2012 study 29123793 2018 11 13 2052-8817 3 3 2016 07 Acute medicine & surgery Acute Med Surg Investigation and treatment of pulmonary embolism as a potential etiology may be important to improve post-resuscitation prognosis in non-shockable out-of-hospital (...) . The subjects were 3,031 adults: (i) who had suffered out-of-hospital cardiac arrest, (ii) for whom there were no pre-hospital data on ventricular fibrillation/pulseless ventricular tachycardia until arrival at hospital, (iii) who experienced the return of spontaneous circulation after arriving at hospital. We compared the patients' prognosis after 1 and 3 months between various etiological and presumed cardiac factors. The proportion of the favorable brain function patients that developed pulmonary embolism

Acute medicine & surgery2016 Full Text: Link to full Text with Trip Pro

78. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score

Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score 26738514 2016 04 01 2016 12 30 2016 12 31 0340-6245 115 4 2016 Apr Thrombosis and haemostasis Thromb. Haemost. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. 827-34 10.1160/TH15-09-0761 The prognostic value of the European Society of Cardiology (ESC) 2014 algorithm and the Bova score has lacked adequate validation. According to the ESC 2014 guidelines (...) and the Bova score, we retrospectively risk stratified normotensive patients with PE who were enrolled in the PROTECT study. This study used a complicated course (which consisted of death from any cause, haemodynamic collapse, or recurrent PE) as the primary endpoint, and follow-up occurred through 30 days after the PE diagnosis. Of 848 patients, 37 % had a sPESI of 0 and 5 (1.6 %; 95 % confidence interval [CI], 0.5-3.7 %) experienced a complicated course. Of 143 patients with a sPESI of 0 points

EvidenceUpdates2016

79. Pulmonary embolism in an adolescent girl with negative ACLA systemic lupus erythematosus (SLE): a case report

Pulmonary embolism in an adolescent girl with negative ACLA systemic lupus erythematosus (SLE): a case report 27053993 2016 04 07 2018 11 13 2008-5842 8 2 2016 Feb Electronic physician Electron Physician Pulmonary embolism in an adolescent girl with negative ACLA systemic lupus erythematosus (SLE): a case report. 1874-9 10.19082/1874 Pulmonary involvement is a common manifestation in systemic lupus erythematosus (SLE), whereas pulmonary thromboembolism (PTE) is rarely seen in SLE. PTE related (...) tomography (HRCT) of the lungs was requested, and it indicated patchy consolidations bilaterally. With suspicion of pulmonary thromboembolism (PTE), spiral computed tomography angiography of pulmonary vessels was done, revealing PTE. After initiation of anti-coagulants, her clinical condition and respiratory status improved significantly. We present a rare case of SLE where only lupus anti-coagulant test was abnormal while other tests, such as anti-cardiolipin antibody and anti-phospholipid antibody were

Electronic physician2016 Full Text: Link to full Text with Trip Pro

80. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy

Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 26422774 2016 01 28 2016 12 20 2016 12 30 0340-6245 115 2 2016 Jan Thrombosis and haemostasis Thromb. Haemost. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. 399-405 10.1160/TH15-02-0172 Pulmonary embolism (PE) is a common disorder with high mortality and morbidity rates. However (...) , population-based information on its incidence and prognosis remains limited. We conducted a large epidemiology study collecting data on hospitalisation for PE (from 2002 to 2012) in a population of about 13 million people in Northwestern Italy. Patients were identified using the ICD-9-CM codes: 415.11, 415.19; gender and age specific incidence rate of PE during the study period were estimated using the resident population for each year of the study. Furthermore, time trends in the in-hospital PE-related

EvidenceUpdates2016